Gyroscope Therapeutics

Founded 2016 Corporate Round Total: $218.20M Biotechnology, Health Care +1

Gyroscope Therapeutics: Gyroscope Therapeutics is a clinical-stage gene therapy company dedicated to developing treatments for eye diseases. The company focuses on integrating advancements in understanding the complement system’s role in eye disease, the genetic foundations of Age-related Macular Degeneration (AMD), and gene therapy as a treatment delivery method. Gyroscope's leading investigational gene therapy, GT005, is administered as a one-time therapy beneath the retina. GT005 aims to rebalance an overactive complement system by boosting the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in a Phase I/II clinical trial FOCUS, as well as in Phase II clinical trials named EXPLORE and HORIZON. The company was founded in 2016 by Andrew Lotery, David Kavanagh, and Peter Lachmann in Stevenage, Herefordshire. Gyroscope Therapeutics received a significant $60.00M Corporate Round investment on 08 November 2021 from Sanofi. The company operates in the Biotechnology and Health Care industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Corporate Round	$60.00M	1	Sanofi	08 Nov 2021
Series C	£107.80M	7	Forbion, Sofinnova Investments +5	26 Mar 2021
Series B	£50.40M	2	Cambridge Innovation Capital, Syncona Investment Management	03 Sep 2019
Seed Round	Undisclosed	-		31 Mar 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Corporate Round

$60.00M

Sanofi

08 Nov 2021

Series C

£107.80M

Forbion, Sofinnova Investments +5

26 Mar 2021

Series B

£50.40M

Cambridge Innovation Capital, Syncona Investment Management

03 Sep 2019

Seed Round

Undisclosed

31 Mar 2017

FAQ About Gyroscope Therapeutics

Gyroscope is a clinical-stage gene therapy company dedicated to developing treatments for eye diseases. The company focuses on integrating advancements in understanding the complement system’s role in eye disease, the genetic foundations of Age-related Macular Degeneration (AMD), and gene therapy as...

Gyroscope Therapeutics was founded in 2016.

Gyroscope Therapeutics operates in Biotechnology, Health Care and Health and Wellness.

Gyroscope Therapeutics has completed 4 funding rounds, raising a total of $218.20M. The latest funding stage is Corporate Round.

Top alternatives and competitors to Gyroscope Therapeutics include Ocular Therapeutix, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Gyroscope Therapeutics and Ocular Therapeutix, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Gyroscope Therapeutics

Funding Rounds & Investors (4)

Gyroscope Therapeutics Alternatives & Competitors

FAQ About Gyroscope Therapeutics